← Back to Search

Central Nervous System Stimulant

Mazindol for Narcolepsy

Phase 2
Waitlist Available
Research Sponsored by NLS Pharmaceutics
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 24 weeks
Awards & highlights

Study Summary

This trial is looking at the long-term effects of a drug called NLS-2 in people with narcolepsy.

Eligible Conditions
  • Narcolepsy

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~24 weeks
This trial's timeline: 3 weeks for screening, Varies for treatment, and 24 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
To evaluate the safety and tolerability of NLS-2 in adult subjects with narcolepsy type 1 (NT1) or narcolepsy type 2 (NT2)

Trial Design

1Treatment groups
Experimental Treatment
Group I: NLS-2 (mazindol extended release)Experimental Treatment1 Intervention
NLS-2 (mazindol extended release) administered once a day.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Mazindol
2021
Completed Phase 2
~60

Find a Location

Who is running the clinical trial?

NLS PharmaceuticsLead Sponsor
3 Previous Clinical Trials
199 Total Patients Enrolled
2 Trials studying Narcolepsy
115 Patients Enrolled for Narcolepsy
Carlos Camozzi, MDStudy DirectorNLS Pharmaceutics
1 Previous Clinical Trials
67 Total Patients Enrolled
1 Trials studying Narcolepsy
67 Patients Enrolled for Narcolepsy

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants have been selected to partake in this experiment?

"This medical trial is presently not recruiting. It was first listed on October 26th 2021 and last updated June 1st 2022. If you are interested in looking at other possibilities, 13 studies for narcolepsy patients are currently enrolling and one study of Mazindol is actively seeking participants."

Answered by AI

Is this particular medical trial a groundbreaking endeavor?

"Mazindol has been studied since 2021 when the pharmaceutical company NLS Pharmaceutics sponsored its first test with 60 participants. After successfully completing Phase 2 drug approval, there is currently only one ongoing study supported by NLS Pharmaceutics."

Answered by AI

Is this research endeavor looking to recruit individuals aged 60 and over?

"Patients aged 18 to 65 are the main target demographic for this trial. There is a seperate cohort of 7 trials dedicated to minors and another 12 designed with seniors in mind."

Answered by AI

Have previous experiments utilized Mazindol to yield meaningful results?

"Currently, one research project is being conducted on Mazindol with no Phase 3 clinical trials in progress. Despite its base location of Stockbridge, Georgia, 22 other facilities are running similar studies."

Answered by AI

Are there still vacancies available for participants in this experiment?

"As per clinicaltrials.gov, this investigation is currently not accepting patients. It was originally launched on October 26th 2021 and last modified June 1st 2022. At present, 14 other trials are actively searching for participants to enrol in their studies."

Answered by AI

How many healthcare facilities in North America are conducting this research endeavor?

"This trial is looking for participants across 22 different locations, such as the Neurology and Sleep Disorders Clinic in Columbia, Ivetmar Medical Group in Miami, and Bogan Sleep Consultants in Dallas."

Answered by AI

Who meets the eligibility criteria for participating in this clinical experiment?

"Sixty individuals will be selected for inclusion in this narcolepsy trial, provided that they are aged between 18 and 65."

Answered by AI

Has Mazindol been given the green light by the FDA?

"Our team at Power assigned Mazindol a score of 2 due to evidence that it is relatively safe in Phase 2 trials, although there isn't enough data yet to prove efficacy."

Answered by AI

Who else is applying?

What state do they live in?
South Carolina
Texas
Other
California
How old are they?
18 - 65
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy
2021. "An Open Label Study of NLS-2 (Mazindol Extended Release) in Subjects With Narcolepsy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05055024.
~15 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top